Products
Lorukafusp Biosimilar Antibody Fusion Protein (GD2) for Research
Cat No.: GMP-Bios-ab-322
Pre-Made Lorukafusp biosimilar, Whole mAb Fusion: Anti-Ganglioside GD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-322-1mg | 1mg | |
| GMP-Bios-ab-322-10mg | 10mg | |
| GMP-Bios-ab-322-100mg | 100mg | |
| GMP-Bios-ab-322-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lorukafusp biosimilar, Whole mAb Fusion: Anti-Ganglioside GD2 therapeutic antibody |
| INN Name | Lorukafusp |
| Target | Ganglioside GD2 |
| Format | Whole mAb Fusion |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma;Neuroblastoma |
| Conditions Discontinued | na |
| Development Tech | na |
